Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Antigen and Activity Assay in Patients With Primary Hypothyroidism

Basit Öğe Kaydı
dc.contributor.authorErmantas, Nilay
dc.contributor.authorGuldiken, Sibel
dc.contributor.authorDemir, Muzaffer
dc.contributor.authorTugrul, Armagan
dc.date.accessioned2024-06-12T11:03:38Z
dc.date.available2024-06-12T11:03:38Z
dc.date.issued2010
dc.departmentTrakya Üniversitesien_US
dc.description.abstractHypothyroidism causes a tendency for cardiovascular diseases. It was recently shown that thrombin-activatable fibrinolysis inhibitor (TAFI) attenuates fibrinolysis and also fibrin-plasminogen interaction by the removal of lysine and arginine residues from fibrin monomers. The aim of this study was to determine the effects of overt hypothyroidism on the levels of TAFI antigen (TAFI Ag) and TAFI activity (TAFIa). Thirty-one overt primary hypothyroid patients and age- and gender-matched 25 healthy controls were enrolled in the study. Patients were treated with L-thyroxine after the collection of blood samples. Thyroid functions were reevaluated following the achievement of euthyroid status. Thrombin-activatable fibrinolysis inhibitor Ag, tissue plasminogen activator (t-PA), and plasminogen activator inhibitor 1 (PAI-1) levels were measured with the enzyme-linked immunosorbent assay (ELISA). Thrombin-activatable fibrinolysis inhibitor activity was assessed with the chromogenic assay. Thrombin-activatable fibrinolysis inhibitor Ag (1.63% +/- 0.42% vs 1.32% +/- 0.36%, P < .01) and TAFIa (14.2 +/- 4.12 vs 11.6 +/- 3.49 mu g/mL, P < .05) levels were elevated in hypothyroid patient compared to controls. Plasminogen activator inhibitor 1 and t-PA levels were not significantly different between both groups. In hypothyroid patients, TAFI Ag levels were correlated with free T-4 (r = -.373, P < .05) and thyroid-stimulating hormone (TSH) levels (r = .748, P < .001). Regression analysis showed that TSH levels were predictors of TAFI Ag levels (P < .001, beta = .671, 95% confidence interval [CI]: 0.008-0.017). Following L-thyroxine treatment, TAFI Ag (1.63% +/- 0.42%, 1.34% +/- 0.33%, P < .05) and TAFIa (14.2 +/- 4.12 mu g/mL, 12.0 +/- 2.77 mu g/mL, P < .05) levels were significantly decreased, but t-PA and PAI-1 levels remained unchanged. This results point out that the fibrinolytic activity was decreased in hypothyroid patients, and therefore the achievement of euthyroid status is important in ameliorating the increased risk of cardiovascular disease.en_US
dc.description.sponsorshipTrakya Universityen_US
dc.description.sponsorshipWe thank the Scientific Project and Research Committee of Trakya University for their generous financial contributions.en_US
dc.identifier.doi10.1177/1076029609350890
dc.identifier.endpage573en_US
dc.identifier.issn1076-0296
dc.identifier.issn1938-2723
dc.identifier.issue5en_US
dc.identifier.pmid19959491en_US
dc.identifier.scopus2-s2.0-77955904716en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage568en_US
dc.identifier.urihttps://doi.org/10.1177/1076029609350890
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21733
dc.identifier.volume16en_US
dc.identifier.wosWOS:000281079400012en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Incen_US
dc.relation.ispartofClinical And Applied Thrombosis-Hemostasisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHypothyroidismen_US
dc.subjectThrombin-Activatable Fibrinolysis Inhibitoren_US
dc.subjectFibrinolytic Systemen_US
dc.subjectTissue Plasminogen Activatoren_US
dc.subjectPlasminogen Activator Inhibitoren_US
dc.subjectL-Thyroxine Treatmenten_US
dc.subjectSubclinical Hypothyroidismen_US
dc.subjectLevothyroxine Replacementen_US
dc.subjectCardiovascular-Diseaseen_US
dc.subjectHypercholesterolemiaen_US
dc.subjectCoagulationen_US
dc.subjectAtherosclerosisen_US
dc.subjectTherapyen_US
dc.subjectPathwayen_US
dc.subjectSystemen_US
dc.titleThrombin-Activatable Fibrinolysis Inhibitor (TAFI) Antigen and Activity Assay in Patients With Primary Hypothyroidismen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu